The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
LLM 2021 | The role of immunotherapy in multiple myeloma
James Berenson, MD, Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, discusses immunotherapy approaches in multiple myeloma treatment. Monoclonal antibodies such as daratumumab and isatuximab, which target CD38, as well as elotuzumab, which targets SLAMF7, have proven to be effective against multiple myeloma as part of combination therapy. Antibody-drug conjugates including the anti-B cell maturation antigen (BCMA) belantamab mafodotin have also shown to demonstrate anti-tumor activity. Dr Berenson additionally describes novel immunotherapy approaches including bi-specific T-cell engagers (BiTEs), and chimeric antigen receptor (CAR)-T cells. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
Disclosures
Speaker’s Bureau, Consulting, and Research Grant Support: BMS, Takeda Oncology, Karyopharm, Oncopeptides, and AMGEN
Speaker’s Bureau: Janssen and AMAG
Major Stockholder: ONCOtracker
